USRE33093E - Bioadhesive extruded film for intra-oral drug delivery and process - Google Patents

Bioadhesive extruded film for intra-oral drug delivery and process Download PDF

Info

Publication number
USRE33093E
USRE33093E US07/272,354 US27235488A USRE33093E US RE33093 E USRE33093 E US RE33093E US 27235488 A US27235488 A US 27235488A US RE33093 E USRE33093 E US RE33093E
Authority
US
United States
Prior art keywords
layer
film
extruded
cellulose
polyethylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/272,354
Inventor
Michael T. Schiraldi
Martin M. Perl
Howard Rubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Inc
Original Assignee
Johnson and Johnson Consumer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/874,904 external-priority patent/US4713243A/en
Application filed by Johnson and Johnson Consumer Products Inc filed Critical Johnson and Johnson Consumer Products Inc
Priority to US07/272,354 priority Critical patent/USRE33093E/en
Application granted granted Critical
Publication of USRE33093E publication Critical patent/USRE33093E/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Definitions

  • the present invention relates to a controlled-releasing medicament-containing preparation for intra-oral use, and is more especially concerned with such a preparation (and the process of using it) in the form of a very thin extruded thermoplastic film (which can be in single layer or laminated multi-layer form) having at least one bioadhesive layer containing .[.40-95.]..Iadd.20-93.Iaddend.% of a thermoplastic cellulose ether and 5-60% of a homopolymer of ethylene oxide which can adhere to the mucosa of the oral cavity.
  • the extruded film drug delivery system of the present invention which has incorporated therein the medicament to be dispensed, is so thin and flexible when wet as to be unobtrusive to the patient after it has been properly positioned and placed in the mouth.
  • HEMA/MMA hydroxyethyl methacrylate/methyl methacrylate copolymer
  • Sodium fluoride is incorporated into the HEMA/MMA matrix to provide sustained fluoride release and enhanced anticaries activity.
  • HEMA/MMA with fluoride may also be attached to the tooth in the form of a wafer-like tablet.
  • Silicone/ethyl cellulose/polyethylene glycol films containing sodium fluoride are applied as coatings on orthodontic bands or in chewing gum. Controlled release of fluoride and anticaries activity is claimed.
  • the above systems are discussed in the "The Compendium of Continuing Education” Vol VI, No. 1, January 1985 p. 27-36 review article "Controlled Drug Delivery: A New Means of Treatment of Dental Disease", by J. Max Goodson, D.D.S., Ph.D. of the Forsyth Dental Center.
  • Other systems described in GB patent application No. 2,042,888 and U.S. Pat. Nos. 4,292,299/4,226,848 (Teijin Ltd., Japan), use combinations of cellulosic and polyacrylate polymers.
  • the preferred materials are hydroxypropyl cellulose ("Klucel”) and a copolymer of acrylic acid (“Carbopol”) that is administered in the form of thin tablets (discs), granules or powder.
  • Other polymers that might be added are vinyl copolymers, polysaccharides, gelatin and collagen.
  • U.S. Pat. No. 4,517,173 (Nippon Soda Co. Ltd, Japan) uses various celluloses in a multi-layered non-extruded cast film preparation.
  • ointments such as ORABASE* with Benzocaine (Squibb), Kenalog* (Triamcinolone Acetonide) in ORABASE* (Squibb) and Mycostatin* (Nystatin) ointment (Squibb).
  • Tablets, appliances, hollow fibers are "bulky" in the mouth, are difficult to keep in place and inconvenient to apply.
  • Ethyl cellulose and/or silicone films do not adhere to mucosal tissue.
  • ORABASE* Ointments
  • the bioadhesive film of the present invention alleviates many of the above problems. It may be applied easily by the consumer. It has very little or no mouthfeel, it has good adhesion to the mucosal tissues, and provides controlled release of the medicament.
  • This technology may also be extended for controlled drug delivery in skin care, gynecological applications, wound care and like uses.
  • the invention involves a pharmaceutically acceptable controlled-releasing medicament-containing extruded single or multi-layered thin film, capable of adhering to a wet mucous surface, comprising a water soluble or swellable polymer matrix bioadhesive layer which can adhere to a wet mucous surface and which bioadhesive layer consists essentially of .[.40-95.Iadd.20-93.Iaddend.% by weight of hydroxypropyl cellulose 5-60% of a homopolymer of ethylene oxide, 0-10% of a water-insoluble polymer selected from the group consisting of ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and 2-10% of a plasticizer, said film having incorporated therein a pharmaceutically effective amount of said medicament.
  • the present invention is directed to an extruded single or multi-layered laminated thin (1-10 mils or 0.025-0.25 mm) film, composed of selected water soluble and/or insoluble polymers.
  • Various therapeutic agents are incorporated into the film during manufacture which are useful for treatment of oral disorders (i.e., denture discomfort, caries, periodontal disease, aphthous ulcers, etc.).
  • the extruded film of the present invention must have at least one bioadhesive layer, but may also have a reservoir layer and/or an outer protective barrier membrane layer.
  • the therapeutic agent may be incorporated into any or all of the layers. When properly formulated and fabricated, these films will adhere to wet mucosal surfaces, provide a protective barrier for injured tissue and deliver controlled/sustained dosages of medication to the infected areas.
  • the film may be designed for localized drug delivery (i.e., the periodontal pocket, an aphthous lesion), or may allow diffusion of the drug into the oral cavity.
  • An example of a non-localized system would be the delivery of sodium fluoride for caries prevention.
  • a single or laminated film with good adhesion to the tooth or mucosal tissue may be employed in which the fluoride release rates may be controlled by varying film solubilities and/or concentration of fluoride in a multi-layered film.
  • An example of a localized application of medication would be in the treatment of aphthous lesions.
  • a laminated two layer film with benzocaine incorporated into the adhesive layer would directly contact the injured mucosa.
  • the outer layer would consist of non-soluble/non-adhesive polymers that provide durability, protection and directs the delivery of benzocaine toward the lesion.
  • the film forming polymers that are useful in this invention are selected from pharmaceutical grade materials, or those that are considered generally regarded as safe (GRAS) as food additives. They include, hydroxypropyl cellulose, and polyethylene oxide homopolymers. Small amounts of other polymers, e.g., polyvinyl ether-maleic acid copolymers and the like may be used in small amounts as well, replacing a small portion of the other polymers.
  • GRAS generally regarded as safe
  • Other polymers e.g., polyvinyl ether-maleic acid copolymers and the like may be used in small amounts as well, replacing a small portion of the other polymers.
  • the above materials are either water soluble of swellable and are most useful in the bioadhesive layer of the film.
  • non-soluble polymers may also be incorporated for modification of the film's permeability properties, such as ethyl cellulose, propyl cellulose, polyethylene, polypropylene and carboxymethylcellulose (free acid).
  • ethyl cellulose, propyl cellulose, polyethylene, polypropylene and carboxymethylcellulose (free acid) By varying the ratios of the above polymers both the solubility and the adhesive properties of each layer of film may be controlled. Therefore, depending on the desired delivery rate, the type of disorder to be treated, the area to be treated and the medication being administered it is possible to custom design the film by selecting and blending various polymers.
  • the final film product may also be fabricated into flexible tapes of varied thickness and width, "spots" of different sizes and shapes or other pre-shaped forms.
  • the medicaments and pharmaceutical agents set forth in the prior art discussed above may generally be delivered by the drug delivery system of the present invention.
  • Usable medicaments are those which are capable of withstanding the heats and pressures generated in the extrusion process involved in making the film of the present invention.
  • Preferred medicaments include:
  • Antibiotics i.e., tetracycline, doxycycline hyclate, meclocycline, minocycline, etc.
  • therapeutic agents that are used to treat oral disorders.
  • the present invention is not to be limited to these specific materials especially where it is intended to deliver drug outside of the oral cavity e.g. to skin where other drugs may be desirable.
  • the film of the present invention has the advantage of being an extruded film, rather than a cast film.
  • the different layers can be coextruded and then laminated together, or else each layer can be separately extruded one on the other, and then laminated together, so that the final multi-layered film is still very thin.
  • the films of the present invention can be made in thicknesses of only 1-10 mils or 0.025-0.25 mm. The films are so thin that when placed in the mouth after they become wet they soon become unobtrusive, and hardly noticeable by most patients.
  • the film must always have a bioadhesive layer, which enables it to adhere to wet mucosal surfaces.
  • the bioadhesive layer has .[.40-95.Iadd.20-93.Iaddend.% of hydroxypropyl cellulose, 5-60% of a homopolymer of ethylene oxide and 2-10% of a glycol plasticizer (all percents are % by weight).
  • HPC Hydroxypropyl cellulose
  • Preferred grades include Klucel MF, with a molecular weight around 600,000 and having a viscosity of 4,000-6,000 cps (Brookfield) in 2 percent water solutions, or Klucel HF, having a molecular weight around 1,000,000 and viscosity of 1500-2500 cps in 1 percent water solution.
  • any HPC having a Molecular Weight above about 100,000 is useful for purposes of this invention.
  • the homopolymer of ethylene oxide useful for purposes of the present invention has a relatively high molecular weight, i.e., above 100,000 and preferably above 3,000,000. Such polymers are commercially available from various sources.
  • the Union Carbide Corporation material, "Polyox WSR-301", which has a molecular weight of approximately 4,000,000-5,000,000 is most preferred for purposes of the present invention.
  • the "plasticizer” useful for purposes of the present invention are selected from glycols such as propylene glycol and polyethylene glycol; polyhydric alcohols such as glycerin and sorbitol; glycerol esters such as glycerol triacetate; fatty acid triglycerides such as NEOBEE* M-5 and MYVEROLS*; mineral oil; vegetable oils such as castor oil, etc.
  • the plasticizer should be non-toxic.
  • the purpose of the plasticizer is to improve polymer melt processing by reducing the polymer melt viscosity and to impart flexibility to the final product.
  • the preferred plasticizer for use in the present invention is either propylene glycol or polyethylene glycol (such as is available from Union Carbide Corporation as their series of Carbowaxes which runs from 200 to 600 molecular weight, of which we prefer to use Carbowax 400, which has a molecular weight of 400, average.
  • the following examples will serve to illustrate the present invention in greater detail.
  • the units shown in the examples are parts by weight.
  • the thickness of the layers is expressed in either mils (0.001 inches) or millimeters. For easy conversion, 4 mils is approximately equal to 0.1 mm.
  • This three layered film laminate is comprised of a "bioadhesive” layer, a sodium fluoride “reservoir” layer and, an “outer protective barrier membrane” layer, in which the composition and thickness of each layer are as shown below:
  • Powder Blending-Each layer is made separately and all ingredients used therein except propylene glycol and Neobee M-5 (liquid plasticizers) are placed in a Patterson Kelley (PK) V-blender equipped with liquid addition capabilities. The ingredients which are all powders are blended for approximately 10-15 minutes while the liquid plasticizer is slowly added to the mix. Three separate powder blends are made, one for each layer.
  • PK Patterson Kelley
  • Each layer is extruded separately with the first layer extruded as a "free film”. Successive layers are extruded onto each other and laminated by passing them through heated stainless steel rollers.
  • test sample is adhered to a glass slide by prewetting the film and placing the bioadhesive layer on the glass surface.
  • the slide is then immersed in a beaker containing 100 ml of distilled water with continuous stirring. Five milliliter aliquots are withdrawn from the solution, at prescribed time intervals, and analyzed for fluoride content with an Orion Ionanalyzer equipped with a fluoride specific electrode. Release rates are then calculated from the data.
  • fluoride release rates in the order of 0.05-0.2 mgs/cm 2 /hr for 24 hours. This falls within the desired range for maintaining constant low levels of fluoride in the mouth and enhanced anticaries activity. Release rates may be tailored to desired use levels by modification of the film composition and construction.
  • composition of the film which was 0.1 mm. thick, was as follows:
  • composition of the film which was 0.1 mm. thick, was as follows:
  • active medicament ingredients may be incorporated into the adhesive films of any of Examples 1-3 in place of the particular medicament used in said examples. These include Benzocaine (analgesic), Potassium nitrate (analgesic), Silver sulfadiazene (antimicrobial),
  • Chlorhexidine antimicrobial
  • miconazole nitrate antifungal
  • Benzethonium chloride antifungal
  • Tetracycline antibiotic
  • This example shows 5 variations of the film having different solubilities, resulting in different release rates.
  • the processing conditions used were similar to those of the bioadhesive layer and outer protective barrier membrane layer of Example I.
  • Part A was extruded on a Johnson extruder followed by subsequent extrusion and lamination of Part B to A.
  • the identical two-layer laminate may also be made by coextruding the inner medicated bioadhesive layer (Part A) and the outer protective barrier layer (Part B) through separate die slots within a coextruder and laminating the two layers together.
  • Example II Following the procedures for the bioadhesive layer of Example I, the powders were blended in P-K blender equipped with liquid addition capabilities. Resulting powders were extruded on a Killion laboratory-sized extruder.
  • the three SSD films each permitted substantially faster wound contraction than that of wounds treated daily with SILVADENE* cream.
  • the films may be scaled up by using an extruder. This example demonstrates the feasibility of such a film to perform its intended purpose. Use of a press for larger samples would result in a non-uniform and lower-quality film than an extruded film.
  • the films were very effective antibacterial agents, while mildly inhibiting wound contraction. They offer clinicians a convenient and more effective delivery system for antimicrobials which can be place in wounds beneath any dressing or can be laminated to any acceptable dressing face.

Landscapes

  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

A bioadhesive extruded single or multi-layered thin film, especially useful in intra-oral controlled-releasing delivery, having a water soluble or swellable polymer matrix bioadhesive layer which can adhere to a wet mucous surface and which bioadhesive layer consists essentially of .[.40-95.]. .Iadd.20-92.Iaddend.% by weight of a hydroxypropyl cellulose 5-60% of a homopolymer of ethylene oxide, 0-10% of a water-insoluble polymer such as ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and 2-10% of a plasticizer, said film having incorporated therein a medicament, e.g. anesthetics, analgesics, anticaries agents, anti-inflammatories, antihistamines, antibiotics, antibacterials, fungistats, etc.

Description

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a controlled-releasing medicament-containing preparation for intra-oral use, and is more especially concerned with such a preparation (and the process of using it) in the form of a very thin extruded thermoplastic film (which can be in single layer or laminated multi-layer form) having at least one bioadhesive layer containing .[.40-95.]..Iadd.20-93.Iaddend.% of a thermoplastic cellulose ether and 5-60% of a homopolymer of ethylene oxide which can adhere to the mucosa of the oral cavity. The extruded film drug delivery system of the present invention, which has incorporated therein the medicament to be dispensed, is so thin and flexible when wet as to be unobtrusive to the patient after it has been properly positioned and placed in the mouth.
2. Description of the Prior Art
Several systems have previously been described which pertain to the delivery of drugs into the oral cavity. These include:
1. Treatment of periodontal disease with tetracycline, chlorhexidine or metronidazole loaded into hollow cellulose acetate fibers. These fibers are packed in the periodontal pockets and provide controlled release of the drug to the infected area.
2. Cast films containing ethyl cellulose/propylene glycol with chlorhexidine or metronidazole for treatment of periodontal disease.
3. An orthodontic appliance with a hydroxyethyl methacrylate/methyl methacrylate copolymer (HEMA/MMA) matrix. Sodium fluoride is incorporated into the HEMA/MMA matrix to provide sustained fluoride release and enhanced anticaries activity. HEMA/MMA with fluoride may also be attached to the tooth in the form of a wafer-like tablet.
4. Silicone/ethyl cellulose/polyethylene glycol films containing sodium fluoride are applied as coatings on orthodontic bands or in chewing gum. Controlled release of fluoride and anticaries activity is claimed. The above systems are discussed in the "The Compendium of Continuing Education" Vol VI, No. 1, January 1985 p. 27-36 review article "Controlled Drug Delivery: A New Means of Treatment of Dental Disease", by J. Max Goodson, D.D.S., Ph.D. of the Forsyth Dental Center. Other systems, described in GB patent application No. 2,042,888 and U.S. Pat. Nos. 4,292,299/4,226,848 (Teijin Ltd., Japan), use combinations of cellulosic and polyacrylate polymers. The preferred materials are hydroxypropyl cellulose ("Klucel") and a copolymer of acrylic acid ("Carbopol") that is administered in the form of thin tablets (discs), granules or powder. Other polymers that might be added are vinyl copolymers, polysaccharides, gelatin and collagen. U.S. Pat. No. 4,517,173 (Nippon Soda Co. Ltd, Japan) uses various celluloses in a multi-layered non-extruded cast film preparation.
Examples of prior art products currently on the market include ointments such as ORABASE* with Benzocaine (Squibb), Kenalog* (Triamcinolone Acetonide) in ORABASE* (Squibb) and Mycostatin* (Nystatin) ointment (Squibb).
The prior art products and delivery systems described above are useful but have the following disadvantages:
Tablets, appliances, hollow fibers are "bulky" in the mouth, are difficult to keep in place and inconvenient to apply.
Ethyl cellulose and/or silicone films do not adhere to mucosal tissue.
Ointments (i.e., ORABASE*) have an unpleasant feel and do not last very long.
Except for ORABASE*, all the foregoing systems require professional application to the tooth or periodontal pockets.
The bioadhesive film of the present invention alleviates many of the above problems. It may be applied easily by the consumer. It has very little or no mouthfeel, it has good adhesion to the mucosal tissues, and provides controlled release of the medicament.
OBJECT OF THE INVENTION
It is an object of this invention to provide an extruded film that is an effective and convenient intra-oral drug delivery system and method for applying and delivering controlled dosages of therapeutic agents into the oral cavity. This technology may also be extended for controlled drug delivery in skin care, gynecological applications, wound care and like uses.
SUMMARY OF THE INVENTION
The invention involves a pharmaceutically acceptable controlled-releasing medicament-containing extruded single or multi-layered thin film, capable of adhering to a wet mucous surface, comprising a water soluble or swellable polymer matrix bioadhesive layer which can adhere to a wet mucous surface and which bioadhesive layer consists essentially of .[.40-95.Iadd.20-93.Iaddend.% by weight of hydroxypropyl cellulose 5-60% of a homopolymer of ethylene oxide, 0-10% of a water-insoluble polymer selected from the group consisting of ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and 2-10% of a plasticizer, said film having incorporated therein a pharmaceutically effective amount of said medicament.
The present invention is directed to an extruded single or multi-layered laminated thin (1-10 mils or 0.025-0.25 mm) film, composed of selected water soluble and/or insoluble polymers. Various therapeutic agents are incorporated into the film during manufacture which are useful for treatment of oral disorders (i.e., denture discomfort, caries, periodontal disease, aphthous ulcers, etc.).
The extruded film of the present invention must have at least one bioadhesive layer, but may also have a reservoir layer and/or an outer protective barrier membrane layer. The therapeutic agent may be incorporated into any or all of the layers. When properly formulated and fabricated, these films will adhere to wet mucosal surfaces, provide a protective barrier for injured tissue and deliver controlled/sustained dosages of medication to the infected areas. The film may be designed for localized drug delivery (i.e., the periodontal pocket, an aphthous lesion), or may allow diffusion of the drug into the oral cavity.
An example of a non-localized system would be the delivery of sodium fluoride for caries prevention. A single or laminated film with good adhesion to the tooth or mucosal tissue may be employed in which the fluoride release rates may be controlled by varying film solubilities and/or concentration of fluoride in a multi-layered film.
An example of a localized application of medication would be in the treatment of aphthous lesions. A laminated two layer film with benzocaine incorporated into the adhesive layer would directly contact the injured mucosa. The outer layer would consist of non-soluble/non-adhesive polymers that provide durability, protection and directs the delivery of benzocaine toward the lesion.
The film forming polymers that are useful in this invention are selected from pharmaceutical grade materials, or those that are considered generally regarded as safe (GRAS) as food additives. They include, hydroxypropyl cellulose, and polyethylene oxide homopolymers. Small amounts of other polymers, e.g., polyvinyl ether-maleic acid copolymers and the like may be used in small amounts as well, replacing a small portion of the other polymers. The above materials are either water soluble of swellable and are most useful in the bioadhesive layer of the film. Various non-soluble polymers may also be incorporated for modification of the film's permeability properties, such as ethyl cellulose, propyl cellulose, polyethylene, polypropylene and carboxymethylcellulose (free acid). By varying the ratios of the above polymers both the solubility and the adhesive properties of each layer of film may be controlled. Therefore, depending on the desired delivery rate, the type of disorder to be treated, the area to be treated and the medication being administered it is possible to custom design the film by selecting and blending various polymers. The final film product may also be fabricated into flexible tapes of varied thickness and width, "spots" of different sizes and shapes or other pre-shaped forms.
The medicaments and pharmaceutical agents set forth in the prior art discussed above may generally be delivered by the drug delivery system of the present invention. Usable medicaments are those which are capable of withstanding the heats and pressures generated in the extrusion process involved in making the film of the present invention. Preferred medicaments include:
Anesthetics/Analgesics-benzocaine, dyclonine HCl, phenol, aspirin, phenacetin, acetaminophen, potassium nitrate, etc.
Anticaries Agents-sodium fluoride, sodium monofluorophosphate, stannous fluoride, etc.
Anti-inflammatories-hydrocortisone acetate, triamcinolone acetonide, dipotassium, glycyrrhizinate, etc.
Antihistamines-chlorpheniramine maleate, ephedrine HCL, diphenhydramine HCL, etc.
Antibiotics-i.e., tetracycline, doxycycline hyclate, meclocycline, minocycline, etc.
Antibacterials-chlorhexidine, cetyl pyridinium chloride, benzethonium chloride, dequalinium chloride, silver sulfadiazene, phenol, thymol, hexedine, hexetidine, alexidine, etc.
Fungistats-nystatin, miconazole, ketoconazole, etc.
The above are illustrative examples of therapeutic agents that are used to treat oral disorders. The present invention is not to be limited to these specific materials especially where it is intended to deliver drug outside of the oral cavity e.g. to skin where other drugs may be desirable.
The film of the present invention has the advantage of being an extruded film, rather than a cast film. When a multi-layered film is involved, the different layers can be coextruded and then laminated together, or else each layer can be separately extruded one on the other, and then laminated together, so that the final multi-layered film is still very thin. The films of the present invention can be made in thicknesses of only 1-10 mils or 0.025-0.25 mm. The films are so thin that when placed in the mouth after they become wet they soon become unobtrusive, and hardly noticeable by most patients.
The film must always have a bioadhesive layer, which enables it to adhere to wet mucosal surfaces. The bioadhesive layer has .[.40-95.Iadd.20-93.Iaddend.% of hydroxypropyl cellulose, 5-60% of a homopolymer of ethylene oxide and 2-10% of a glycol plasticizer (all percents are % by weight).
The Hydroxypropyl cellulose (HPC), useful for purposes of the present invention is commercially available from Hercules, Inc. (Wilmington, DE) under the tradename KLUCEL*. Preferred grades include Klucel MF, with a molecular weight around 600,000 and having a viscosity of 4,000-6,000 cps (Brookfield) in 2 percent water solutions, or Klucel HF, having a molecular weight around 1,000,000 and viscosity of 1500-2500 cps in 1 percent water solution. In general, any HPC having a Molecular Weight above about 100,000 is useful for purposes of this invention.
The homopolymer of ethylene oxide useful for purposes of the present invention has a relatively high molecular weight, i.e., above 100,000 and preferably above 3,000,000. Such polymers are commercially available from various sources. The Union Carbide Corporation material, "Polyox WSR-301", which has a molecular weight of approximately 4,000,000-5,000,000 is most preferred for purposes of the present invention.
The "plasticizer" useful for purposes of the present invention are selected from glycols such as propylene glycol and polyethylene glycol; polyhydric alcohols such as glycerin and sorbitol; glycerol esters such as glycerol triacetate; fatty acid triglycerides such as NEOBEE* M-5 and MYVEROLS*; mineral oil; vegetable oils such as castor oil, etc.
For the uses for the present invention contemplated here, the plasticizer should be non-toxic. The purpose of the plasticizer is to improve polymer melt processing by reducing the polymer melt viscosity and to impart flexibility to the final product.
The preferred plasticizer for use in the present invention is either propylene glycol or polyethylene glycol (such as is available from Union Carbide Corporation as their series of Carbowaxes which runs from 200 to 600 molecular weight, of which we prefer to use Carbowax 400, which has a molecular weight of 400, average.
In addition to the polymers and plasticizer which are required ingredients of the films of the present invention, minor amounts of other non-essential but customary ingredients will often be used if desired, e.g., antioxidants, preservatives, flavors, colorants.
DETAILED DESCRIPTION
The following examples will serve to illustrate the present invention in greater detail. The units shown in the examples are parts by weight. The thickness of the layers is expressed in either mils (0.001 inches) or millimeters. For easy conversion, 4 mils is approximately equal to 0.1 mm.
EXAMPLE 1
Triple Layered Laminate Containing Sodium Fluoride for Anticaries Protection
This three layered film laminate is comprised of a "bioadhesive" layer, a sodium fluoride "reservoir" layer and, an "outer protective barrier membrane" layer, in which the composition and thickness of each layer are as shown below:
______________________________________                                    
                                   Outer                                  
                                   Protective                             
                Bio-     % w/w     Barrier                                
                adhesive Reservoir Membrane                               
                Layer    Layer     Layer                                  
                (4 mils) (1 mil)   (1 mil)                                
Ingredients     (0.1 mm) (0.025 mm)                                       
                                   (0.025 mm)                             
______________________________________                                    
Polyethylene oxide                                                        
                60.0     --        --                                     
homopolymer (Unison                                                       
Carbide-Polyox* WSR-301)                                                  
Hydroxypropyl Cellulose                                                   
                30.0     20.0      24.0                                   
(Hercules, Inc.-Klucel* MF)                                               
Polyethylene (Allied                                                      
                5.0      --        --                                     
Chemical-6A)                                                              
(Low Density)                                                             
Propylene Glycol, U.S.P.                                                  
                3.0      --        --                                     
Polyethylene Glycol                                                       
                2.0      --        --                                     
400 (Union Carbide)                                                       
Ethyl Cellulose (Hercules,                                                
                --       59.0      69.6                                   
Inc.-N100F)                                                               
Caprylic/Capric --        5.0      6.0                                    
Triglyceride(PVO                                                          
Incorporated-Neobee M-5)                                                  
Sodium Fluoride, U.S.P.                                                   
                --       16.0      0.4                                    
                100.0    100.0     100.0                                  
______________________________________
The process used to make the above laminate was:
a. Powder Blending-Each layer is made separately and all ingredients used therein except propylene glycol and Neobee M-5 (liquid plasticizers) are placed in a Patterson Kelley (PK) V-blender equipped with liquid addition capabilities. The ingredients which are all powders are blended for approximately 10-15 minutes while the liquid plasticizer is slowly added to the mix. Three separate powder blends are made, one for each layer.
b. Extrusion Process-A standard Johnson 2-1/2 inch vinyl/polyolefin extruder equipped with a single three stage screw was used to extrude the "powder blend". The temperature conditions for the water soluble powders are however quite different from those used for vinyls and polyolefins. The temperature (°C.) profile for the "reservoir" and "membrane layers" of the triple laminate was as follows:
______________________________________                                    
       Barrel Zone 1                                                      
                 100                                                      
       Barrel Zone 2                                                      
                 125                                                      
       Barrel Zone 3                                                      
                 135                                                      
       Barrel Zone 4                                                      
                 145                                                      
       Barrel Zone 5                                                      
                 160                                                      
       Barrel Zone 6                                                      
                 170                                                      
       Adapter   180                                                      
       Die Zone 1                                                         
                 180                                                      
       Die Zone 2                                                         
                 180                                                      
       Die Zone 3                                                         
                 180                                                      
______________________________________
The films which had a width of 18 inches, were extruded at approximately 20 feet/minute through a flat lipped die. The temperature profile for the "bioadhesive layer" was:
______________________________________                                    
       Barrel Zone 1                                                      
                 125                                                      
       Barrel Zone 2                                                      
                 140                                                      
       Barrel Zone 3                                                      
                 165                                                      
       Barrel Zone 4                                                      
                 170                                                      
       Barrel Zone 5                                                      
                 185                                                      
       Barrel Zone 6                                                      
                 185                                                      
       Adapter   185                                                      
       Die Zone 1                                                         
                 185                                                      
       Die Zone 2                                                         
                 185                                                      
       Die Zone 3                                                         
                 185                                                      
______________________________________
Each layer is extruded separately with the first layer extruded as a "free film". Successive layers are extruded onto each other and laminated by passing them through heated stainless steel rollers.
Test Results:
In vitro fluoride ion release studies were conducted on samples of the above described triple laminate film measuring 0.5 cm×1.25 cm (0.625 cm2) according to the following procedures:
The test sample is adhered to a glass slide by prewetting the film and placing the bioadhesive layer on the glass surface. The slide is then immersed in a beaker containing 100 ml of distilled water with continuous stirring. Five milliliter aliquots are withdrawn from the solution, at prescribed time intervals, and analyzed for fluoride content with an Orion Ionanalyzer equipped with a fluoride specific electrode. Release rates are then calculated from the data.
The results obtained indicated fluoride release rates in the order of 0.05-0.2 mgs/cm2 /hr for 24 hours. This falls within the desired range for maintaining constant low levels of fluoride in the mouth and enhanced anticaries activity. Release rates may be tailored to desired use levels by modification of the film composition and construction.
EXAMPLE 2
Single Layer Adhesive Film Containing Hydrocortisone Acetate (0.5%) As An Anti-Inflammatory Agent
The composition of the film, which was 0.1 mm. thick, was as follows:
______________________________________                                    
Ingredients           % w/w                                               
______________________________________                                    
Ethylene Oxide Homopolymer                                                
                      59.4                                                
(Polyox* WSR-301)                                                         
Hydroxypropyl Cellulose                                                   
                      30.0                                                
(Klucel* MF)                                                              
Polyethylene (AC-6A)  5.0                                                 
Propylene Glycol      3.0                                                 
Polyethylene Glycol 400                                                   
                      2.0                                                 
Butylated Hydroxy Toluene (BHT)                                           
                      0.1                                                 
FCC (preservative)                                                        
Hydrocortisone Acetate                                                    
                      0.5                                                 
                      100.0                                               
______________________________________
The powder blending process and extruder conditions used were the same as those described in Example I for the "bioadhesive layer" of the sodium fluoride trilaminate. In vitro tests were performed on the above film and demonstrated a prolonged drug release pattern.
EXAMPLE 3
Single Layer Adhesive Film Containing Triamcinolone Acetonide (0.1%) As An Anti-Inflammatory
The composition of the film, which was 0.1 mm. thick, was as follows:
______________________________________                                    
Ingredients          % w/w                                                
______________________________________                                    
Ethylene Oxide Homopolymer                                                
                     59.9                                                 
(Polyox WSR-301)                                                          
Hydroxypropyl Cellulose                                                   
                     29.9                                                 
(Klucel MF)                                                               
Polyethylene (AC-6A) 5.0                                                  
Propylene Glycol     3.0                                                  
Polyethylene Glycol 400                                                   
                     2.0                                                  
BHT                  0.1                                                  
Triamcinolone Acetonide                                                   
                     0.1                                                  
                     100.0                                                
______________________________________
The powder blending process and extruder conditions used to make the film of this Example 3 were the same as those of the "bioadhesive layer" of Example I.
Other desired active medicament ingredients may be incorporated into the adhesive films of any of Examples 1-3 in place of the particular medicament used in said examples. These include Benzocaine (analgesic), Potassium nitrate (analgesic), Silver sulfadiazene (antimicrobial),
Chlorhexidine (antimicrobial), miconazole nitrate (antifungal), Benzethonium chloride (antimicrobial), Tetracycline (antibiotic) and other similar therapeutic compounds.
EXAMPLE 4
Analgesic Films with Potassium Nitrate
This example shows 5 variations of the film having different solubilities, resulting in different release rates.
______________________________________                                    
              % w/w                                                       
Ingredients     1      2       3    4     5                               
______________________________________                                    
Polyethylene oxide                                                        
                23.75  57.00   55.00                                      
                                    55.00 57.00                           
homopolymer (Polyox*                                                      
WSR-301)                                                                  
Hydroxypropyl Cell-                                                       
                68.30  --      --   --    --                              
ulose, N.F. (Klucel* HF)                                                  
Hydroxypropyl Cell-                                                       
                --     28.40   29.90                                      
                                    22.40 22.40                           
ulose, N.F. (Klucel* MF)                                                  
Ethyl Cellulose --     4.75    5.00 12.50 12.50                           
Polyethylene Glycol 400                                                   
                1.90   1.90    2.00 2.00  2.00                            
Polyethylene Glycol 8000                                                  
                0.95   --      --   --    --                              
Propylene Glycol, U.S.P.                                                  
                --     2.85    3.00 3.00  3.00                            
BHT, F.C.C.     0.10   0.10    0.10 0.10  0.10                            
Potassium Nitrate, F.C.C.                                                 
                5.00   5.00    5.00 5.00  3.00                            
______________________________________
The above ingredients are blended in a Patterson-Kelly powder blender equipped with liquid addition capabilities. The resulting powder blend is then extruded into film on a Killion or Johnson vinyl extruder using processing procedures similar to those of the bioadhesive layer of Example I.
example 5
Anesthetic Films with Benzocaine (Laminate)
This is an example of a two-layer laminate. The processing conditions used were similar to those of the bioadhesive layer and outer protective barrier membrane layer of Example I.
______________________________________                                    
A.      Inner medicated bioadhesive layer                                 
        Polyoxyethylene Homopolymer                                       
                             57.00                                        
        (Polyox* WSR-301)                                                 
        Hydroxypropyl Cellulose, N.F.                                     
                             28.40                                        
        (Klucel* MF)                                                      
        Polyethylene (AC-6A) 4.75                                         
        Propylene Glycol, U.S.P.                                          
                             2.85                                         
        Polyethylene Glycol 400                                           
                             1.90                                         
        BHT, F.C.C.          0.10                                         
        Benzocaine, U.S.P.   5.00                                         
                             100.00                                       
B.      Outer protective/barrier layer                                    
        Hydroxypropyl Cellulose                                           
                             78.00                                        
        (Klucel* MF)                                                      
        Ethyl Cellulose      20.00                                        
        Polyethylene Glycol 400                                           
                             2.00                                         
                             100.00                                       
______________________________________
Part A was extruded on a Johnson extruder followed by subsequent extrusion and lamination of Part B to A.
Samples were applied to oral lesions, and provided profound anesthetic effects (lasting several hours) within minutes of application.
The identical two-layer laminate may also be made by coextruding the inner medicated bioadhesive layer (Part A) and the outer protective barrier layer (Part B) through separate die slots within a coextruder and laminating the two layers together.
EXAMPLE 6
Anesthetic Films with Phenol and Dyclonine HCl
Four variations of a single layer bioadhesive film were made as shown below:
______________________________________                                    
Ingredients      1      2        3    4                                   
______________________________________                                    
Polyethylene oxide homo-                                                  
                 59.10  54.00    59.70                                    
                                      58.20                               
polymer (Polyox* WSR-301)                                                 
Hydroxypropyl Cellulose                                                   
                 29.45  26.91    29.75                                    
                                      29.00                               
(Klucel HF)                                                               
Ethyl Cellulose  4.93   4.50     4.98 4.85                                
Propylene Glycol, U.S.P.                                                  
                 2.96   2.70     2.99 2.91                                
Polyethylene Glycol 400                                                   
                 1.97   1.80     1.99 1.94                                
BHT, F.C.C.      0.09   0.09     0.09 0.10                                
Phenol, U.S.P.   1.50   --       --   --                                  
Dyclonine HCl    --     10.00    0.50 3.00                                
______________________________________
Following the procedures for the bioadhesive layer of Example I, the powders were blended in P-K blender equipped with liquid addition capabilities. Resulting powders were extruded on a Killion laboratory-sized extruder.
EXAMPLE 7
Silver Sulfadiazene Films-Antimicrobial
Three different single-layered bioadhesive films containing 1.0% 0.5% and 0.5% respectively of silver sulfadiazene (SSD) were prepared on a heated Carver laboratory press (designed to simulate extruded conditions) as shown below.
______________________________________                                    
                   % w/w                                                  
Ingredients          A       B                                            
______________________________________                                    
Polyethylene oxide homopolymer                                            
                     60.00   60.00                                        
(Polyox* WSR-301)                                                         
Hydroxypropyl Cellulose                                                   
                     28.9    29.4                                         
(Klucel* HF)                                                              
Polyethylene (AC-6A) 5.0     5.0                                          
Propylene Glycol, U.S.P.                                                  
                     3.0     3.0                                          
Polyethylene Glycol 400                                                   
                     2.0     2.0                                          
BHT, F.C.C.          0.1     0.1                                          
Silver Sulfadiazine  1.0     0.5                                          
                     100.0   100.0                                        
______________________________________
Effects on wound repair and activity against Staphylococcus aureus were evaluated in the guinea pig model. Full-thickness excisions were inoculated with 3.8×105 organisms, (Staph. aureus) and wound surface microbiology samples taken 10 minutes and 24 hours after treatment. Test films were placed on the wound and covered with BIOCLUSIVE* Transparent Dressings secured with elastic tape. Wound contraction was measured over an eight-day period using OPTOMAX* Computer-Assisted Image Analysis. The three films tested were the following:
A. 1.0% Silver Sulfadiazene, 125° C./2 minutes/4 tons
B. 0.5% Silver Sulfadiazene, 125° C./2 minutes/4 tons
C. 0.5% Silver Sulfadiazene, 150° C./3 minutes/4 tons
SILVADENE Cream and an untreated occluded control. The results indicated that:
1. SILVADENE* treated wounds significantly inhibited full-thickness wound contraction.
2. Film A, B and C inhibited wound contraction relative to that of BIOCLUSIVE* dressed wounds.
3. The three SSD films each permitted substantially faster wound contraction than that of wounds treated daily with SILVADENE* cream.
4. All films were very active against S. Aureus 24 hours after inoculation.
The films may be scaled up by using an extruder. This example demonstrates the feasibility of such a film to perform its intended purpose. Use of a press for larger samples would result in a non-uniform and lower-quality film than an extruded film.
Based on the above findings, the films were very effective antibacterial agents, while mildly inhibiting wound contraction. They offer clinicians a convenient and more effective delivery system for antimicrobials which can be place in wounds beneath any dressing or can be laminated to any acceptable dressing face.

Claims (9)

What is claimed is:
1. A pharmaceutically acceptable controlled-releasing medicament-containing extruded single or multi-layered thin film, capable of adhering to a wet mucous surface, comprising a water soluble or swellable polymer matrix bioadhesive layer which can adhere to a wet mucous surface and which bioadhesive layer consists essentially of .[.40-95.]..Iadd.20-93.Iaddend.% by weight of a hydroxypropyl cellulose having a molecular weight above 100,000, 5-60% of a homopolymer of ethylene oxide having a molecular weight from 3,000,000 to 5,000,000, 0-10% of a water-insoluble polymer selected from the group consisting of ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and 2-10% of a plasticizer, said film having incorporated therein a pharmaceutically effective amount of said medicament.
2. The extruded film of claim 1, made in a form which is so thin and flexible when wet as to be unobtrusive to the patient when properly positioned and placed in the patients mouth.
3. The extruded film of claim 2 having a thickness no greater than 0.25 millimeters.
4. The extruded film of claim 1, in single layer form, which also contains up to 10% by weight of a non-soluble polymer selected from the group consisting of ethyl cellulose, polyethylene, polypropylene and carboxymethyl cellulose free acid.
5. The extruded film of claim 1, in multi-layer laminated form, which is addition to the bioadhesive layer also contains a reservoir layer in which at least a major portion of the medicament is contained.
6. The extruded multi-layer film of claim 5 in which the reservoir layer consists essentially of a polymer matrix comprised of both a water soluble or swellable polymer and a non-water soluble polymer selected from the group consisting of ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and also hydroxypropyl cellulose.
7. The extruded film of claim 1 in multi-layer laminated form, which in addition to the bioadhesive layer also contains an outer protective-barrier membrane layer.
8. The extruded multi-layer film of claim 7 in which the outer protective-barrier membrane layer is thinner than the bioadhesive layer, and said outer protective barrier layer consists essentially of a polymer matrix of a major proportion of a non-water-soluble polymer selected from the group consisting of ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and a minor proportion of hydroxypropyl cellulose.
9. The extruded multi-layer film of claim 1 in the form of a triple layered laminate containing sodium fluoride for anticaries protection having the following composition:
______________________________________                                    
                                   Outer                                  
                                   Protective                             
                Bio-     % w/w     Barrier                                
                adhesive Reservoir Membrane                               
                Layer    Layer     Layer                                  
Ingredients     (0.1 mm) (0.025 mm)                                       
                                   (0.025 mm)                             
______________________________________                                    
Polyethylene oxide                                                        
                60.0     --        --                                     
homopolymer                                                               
(MW 3,000,000 minimum)                                                    
Hydroxypropyl Cellulose                                                   
                30.0     20.0      24.0                                   
(MW 1,000,000)                                                            
Polyethylene (Low Density)                                                
                5.0      --        --                                     
Propylene Glycol U.S.P.                                                   
                3.0      --        --                                     
Polyethylene Glycol                                                       
                2.0      --        --                                     
(MW 400)                                                                  
Ethyl Cellulose --       59.0      69.6                                   
Caprylic/Capric --        5.0      6.0                                    
Triglyceride                                                              
Sodium Flouride --       16.0      0.4                                    
                100.0    100.0     100.0                                  
______________________________________
US07/272,354 1986-06-16 1988-11-16 Bioadhesive extruded film for intra-oral drug delivery and process Expired - Lifetime USRE33093E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/272,354 USRE33093E (en) 1986-06-16 1988-11-16 Bioadhesive extruded film for intra-oral drug delivery and process

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/874,904 US4713243A (en) 1986-06-16 1986-06-16 Bioadhesive extruded film for intra-oral drug delivery and process
US07/272,354 USRE33093E (en) 1986-06-16 1988-11-16 Bioadhesive extruded film for intra-oral drug delivery and process

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US06/874,904 Reissue US4713243A (en) 1986-06-16 1986-06-16 Bioadhesive extruded film for intra-oral drug delivery and process

Publications (1)

Publication Number Publication Date
USRE33093E true USRE33093E (en) 1989-10-17

Family

ID=26955461

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/272,354 Expired - Lifetime USRE33093E (en) 1986-06-16 1988-11-16 Bioadhesive extruded film for intra-oral drug delivery and process

Country Status (1)

Country Link
US (1) USRE33093E (en)

Cited By (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997830A (en) * 1990-02-07 1991-03-05 The Research Foundation Of State University Of New York Pharmaceutical composition for the treatment of periodontitis
US5064650A (en) * 1988-04-19 1991-11-12 Southwest Research Institute Controlled-release salt sensitive capsule for oral use and adhesive system
US5112620A (en) * 1990-09-20 1992-05-12 Mikkur, Inc. Polyethylene glycol ointment for apthous ulcers
WO1992007640A1 (en) * 1990-10-29 1992-05-14 Fmc Corporation Polysaccharide-based porous sheets
US5114718A (en) * 1990-09-20 1992-05-19 The Procter & Gamble Company Sustained release compositions for treating periodontol disease
US5133971A (en) * 1988-12-14 1992-07-28 Phoebe Copelan Personal dental hygiene assembly
US5135752A (en) * 1988-10-14 1992-08-04 Zetachron, Inc. Buccal dosage form
US5262164A (en) * 1989-11-17 1993-11-16 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5288532A (en) * 1990-08-28 1994-02-22 Viskase Corporation Transferable modifier-containing film
EP0598606A1 (en) * 1992-11-18 1994-05-25 JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. Extrudable compositions for topical or transdermal drug delivery
US5364634A (en) * 1991-11-08 1994-11-15 Southwest Research Institute Controlled-release PH sensitive capsule and adhesive system and method
US5447725A (en) * 1993-06-11 1995-09-05 The Procter & Gamble Company Methods for aiding periodontal tissue regeneration
US5700478A (en) * 1993-08-19 1997-12-23 Cygnus, Inc. Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
US5714165A (en) * 1990-09-20 1998-02-03 Mikkur, Inc. Bioadhesive polyethylene glycol ointment for medicaments
US5851551A (en) * 1991-08-23 1998-12-22 The Gillette Company Sustained-release matrices for dental application
US5894017A (en) * 1997-06-06 1999-04-13 The Procter & Gamble Company Delivery system for an oral care substance using a strip of material having low flexural stiffness
US5906814A (en) * 1995-12-07 1999-05-25 The Andrew Jergens Company Topical film-forming compositions
US5906834A (en) * 1992-06-15 1999-05-25 The Gillette Company Color changing matrix as wear indicator
US5914118A (en) 1995-12-26 1999-06-22 Sanwa Kagaku Kenkyusho Co., Ltd. Multi-layered drug containing film preparation having powder adhesive thereon
US5958452A (en) 1994-11-04 1999-09-28 Euro-Celtique, S.A. Extruded orally administrable opioid formulations
US6068855A (en) 1994-11-03 2000-05-30 Euro-Celtique S. A. Pharmaceutical composition containing a fusible carrier and method for producing the same
US6153210A (en) 1997-08-14 2000-11-28 Periodontix, Inc. Use of locally delivered metal ions for treatment of periodontal disease
US6231957B1 (en) 1999-05-06 2001-05-15 Horst G. Zerbe Rapidly disintegrating flavor wafer for flavor enrichment
US6375963B1 (en) 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
US6419906B1 (en) * 2001-03-12 2002-07-16 Colgate Palmolive Company Strip for whitening tooth surfaces
US6503486B2 (en) * 2001-03-12 2003-01-07 Colgate Palmolive Company Strip for whitening tooth surfaces
US6514483B2 (en) * 2001-03-12 2003-02-04 Colgate Palmolive Company Strip for whitening tooth surfaces
US20030053962A1 (en) * 2001-06-19 2003-03-20 Zerbe Horst G. Flavored film
US20030059381A1 (en) * 1997-06-06 2003-03-27 Goodhart Lesle Marie Structures and compositions increasing the stability of peroxide actives
US6551579B2 (en) 1997-06-06 2003-04-22 The Procter & Gamble Company Delivery systems for a tooth whitener
US6562363B1 (en) 1997-09-26 2003-05-13 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6566350B2 (en) * 2000-05-23 2003-05-20 Showa Yakuhin Kako Co., Ltd. Minocycline-containing compositions
US6582708B1 (en) 2000-06-28 2003-06-24 The Procter & Gamble Company Tooth whitening substance
US20030167556A1 (en) * 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
US6638881B2 (en) 1999-12-23 2003-10-28 Combe Incorporated Dental adhesive device and method of producing same
US6682721B2 (en) 2000-03-17 2004-01-27 Lg Household & Healthcare Ltd. Patches for teeth whitening
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6689344B2 (en) 2000-03-17 2004-02-10 Lg Household & Healthcare Ltd. Patches for teeth whitening
US20040120991A1 (en) * 2002-09-07 2004-06-24 Mars Incorporated Edible films having distinct regions
US20040146836A1 (en) * 2003-01-24 2004-07-29 Andersen Scot N. Pre-shaped dental trays and treatment devices and methods that utilize such dental trays
US20040219111A1 (en) * 2000-03-17 2004-11-04 Ji-Young Kim Method and device for teeth whitening using a dry type adhesive
US20040241616A1 (en) * 2003-05-27 2004-12-02 Ultradent Products, Inc. Substantially solid bleaching composition in a tray-like configuration
US20040241615A1 (en) * 2003-05-27 2004-12-02 Allred Peter M. Tray-like dental bleaching devices having a barrier layer and a substantially solid bleaching composition
US20040241294A1 (en) * 2003-05-31 2004-12-02 Barabolak Roman M. Edible films including aspartame and methods of making same
US20040241617A1 (en) * 2003-05-27 2004-12-02 Allred Peter M. Substantially solid desensitizing compositions and devices having a tray-like configuration and methods of manufacturing and using such compositions and devices
US20040258896A1 (en) * 2001-10-12 2004-12-23 Monosolrx Llc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20050037055A1 (en) * 2002-04-11 2005-02-17 Monosolrx Llc. Polyethylene oxide-based films and drug delivery systems made therefrom
US6860736B2 (en) 2003-05-23 2005-03-01 Ultradent Products, Inc. Oral treatment devices that include a thin, flexible barrier layer and an endoskeleton treatment or adhesive composition
US6884426B2 (en) 1997-06-06 2005-04-26 The Procter & Gamble Co. Methods for whitening teeth
US20050089820A1 (en) * 2003-10-22 2005-04-28 Allred Peter M. Treatment compositions and strips having a solid adhesive layer and treatment gel adjacent thereto
US20050100515A1 (en) * 2002-09-11 2005-05-12 The Procter & Gamble Company Tooth whitening products
US20050136381A1 (en) * 2003-01-24 2005-06-23 Andersen Scot N. Preshaped thin-walled dental trays and methods of manufacturing and using such trays
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20050186150A1 (en) * 2004-02-19 2005-08-25 Allred Peter M. Dental bleaching devices having a protective adhesive region
US20050186539A1 (en) * 2004-02-19 2005-08-25 Mclean Bruce S. Universal tray design having anatomical features to enhance fit
US20050196443A1 (en) * 2001-08-22 2005-09-08 Isis Pharmaceuticals, Inc. Pulsatile release compositions and methods for enhanced intestinal drug absorption
US6946142B2 (en) 2001-06-23 2005-09-20 Lg Household & Healthcare Ltd. Multi-layer patches for teeth whitening
US20050208108A1 (en) * 2004-03-19 2005-09-22 Jannusch Leonard C Thermoplastic films and methods for making
US6949240B2 (en) 2002-05-23 2005-09-27 The Procter & Gamble Company Tooth whitening products
US6981874B2 (en) 2003-10-22 2006-01-03 Ultradent Products, Inc. Dental bleaching compositions and devices having a solid activation adhesive layer or region and bleaching gel layer or region
US7011523B2 (en) 2003-10-22 2006-03-14 Ultradent Products, Inc. Bleaching compositions and devices having a solid adhesive layer and bleaching gel adjacent thereto
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US7040897B2 (en) 2003-05-23 2006-05-09 Ultradent Products, Inc. Thin, flexible membrane dental trays and systems and methods utilizing such trays
US7052275B2 (en) 2003-05-27 2006-05-30 Ultradent Products, Inc. Kits and methods for bleaching and desensitizing teeth
EP1659976A2 (en) * 2003-08-08 2006-05-31 Ultradent Products, Inc. Compositons and devices having a tray-like configuration for delivering an oral medicament and methods of manufacturing and using such compositions and devices
US20060115785A1 (en) * 2004-11-30 2006-06-01 Chunhua Li Systems and methods for intra-oral drug delivery
US20060115782A1 (en) * 2004-11-30 2006-06-01 Chunhua Li Systems and methods for coating a dental appliance
US20060116561A1 (en) * 2004-11-30 2006-06-01 Tricca Robert E Systems and methods for intra-oral diagnosis
US20060171905A1 (en) * 2005-01-31 2006-08-03 Allred Peter M Dental bleaching compositions having a protective coating applied thereto
US20060172260A1 (en) * 2005-01-31 2006-08-03 Allred Peter M Dental tray system with releasable hold inner and outer dental trays
US20060207721A1 (en) * 2005-03-17 2006-09-21 Greg Slominski Polymer adhesive splicing of water-soluble, orally ingestible thin film webs
US20070172515A1 (en) * 2006-01-20 2007-07-26 Monosolrx, Llc Film bandage for mucosal administration of actives
US7264471B2 (en) 2004-05-05 2007-09-04 Ultradent Products, Inc. Methods and kits for bleaching teeth while protecting adjacent gingival tissue
WO2007112285A2 (en) 2006-03-24 2007-10-04 Auxilium Pharmaceuticals, Inc. Process for the preparation of a hot-melt extruded laminate
US20070298380A1 (en) * 2006-06-26 2007-12-27 Ultradent Products, Inc. Dental treatment devices adapted for improved lingual side adhesion
US20070298087A1 (en) * 2006-06-27 2007-12-27 Biegajski James E Two-phase mucoadhesive composition
US7338664B2 (en) 1991-08-23 2008-03-04 The Gillette Company Color changing matrix as wear indicator
US20080075825A1 (en) * 2006-09-20 2008-03-27 Fuisz Richard C Edible Water-Soluble Film Containing a Foam Reducing Flavoring Agent
US20080119698A1 (en) * 2004-11-30 2008-05-22 Tricca Robert E Systems and methods for intra-oral diagnosis
US20080200452A1 (en) * 2005-07-20 2008-08-21 Petra Obermeier Oral, Rapidly Disintegrating Film, Which Cannot be Spat Out, for a Neuroleptic
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20080234200A1 (en) * 2003-12-26 2008-09-25 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US7452209B2 (en) 2005-05-02 2008-11-18 Ultradent Products, Inc. Exoskeleton support for placement of a dental treatment strip
US20080292683A1 (en) * 2007-05-24 2008-11-27 Monosolrx, Llc. Film shreds and delivery system incorporating same
US20080299005A1 (en) * 2003-10-24 2008-12-04 Meathrel William G Disintegratable films for diagnostic devices
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20080318861A1 (en) * 2005-12-08 2008-12-25 Nastech Pharmaceutical Company Inc. Mucosal Delivery of Stabilized Formulations of Exendin
EP2010156A2 (en) * 2006-03-24 2009-01-07 Auxilium International Holdings, Inc. Stabilized compositions containing alkaline labile drugs
US20090087812A1 (en) * 2007-10-02 2009-04-02 Ultradent Products, Inc. Self-customizable dental treatment trays
US20090095313A1 (en) * 2007-10-11 2009-04-16 Fuisz Richard C Smokeless Tobacco Product, Smokeless Tobacco Product in the Form of a Sheet, Extrudable Tobacco Composition, Method for Manufacturing a Smokeless Tobacco Product, Method for Delivering Super Bioavailable Nicotine Contained in Tobacco to a User, and Packaged Smokeless Tobacco Product Sheet
WO2009048522A1 (en) 2007-10-11 2009-04-16 Richard Fuisz Smokeless tobacco product
US20090098192A1 (en) * 2007-10-11 2009-04-16 Fuisz Richard C Extrudable and Extruded Compositions for Delivery of Bioactive Agents, Method of Making Same and Method of Using Same
US20090130058A1 (en) * 2006-01-19 2009-05-21 Hall Mark J Biologically active composition comprising ethylcellulose
US7625210B2 (en) 2004-08-09 2009-12-01 Ultradent Products, Inc. Treatment devices for providing oral treatments and kits and methods that utilize such treatment devices
US20100028829A1 (en) * 2008-07-31 2010-02-04 Ultradent Products, Inc. Chemically activated dental bleaching trays
US20100040727A1 (en) * 2008-08-18 2010-02-18 Monosol Rx, Llc Method for Improving Uniformity of Content in Edible Film Manufacturing
US20100150987A1 (en) * 2008-12-15 2010-06-17 Monosol Rx, Llc Method for Manufacturing Edible Film
US20100221309A1 (en) * 2001-10-12 2010-09-02 Monosol Rx, Llc Film compositions for delivery of actives
US20100285130A1 (en) * 2009-05-06 2010-11-11 Monosol Rx, Llc Coating of complexed actives in film formulations
US20100297232A1 (en) * 2009-05-19 2010-11-25 Monosol Rx, Llc Ondansetron film compositions
US20110009834A1 (en) * 2008-03-15 2011-01-13 Lts Lohmann Therapie-Systeme Ag Gingival wafer
US7910641B2 (en) 2001-10-12 2011-03-22 Monosol Rx, Llc PH modulated films for delivery of actives
US20110086329A1 (en) * 2004-11-10 2011-04-14 Ranir/Dcp Corporation Device and method for delivering an oral care agent
US20110142942A1 (en) * 2009-12-10 2011-06-16 Monosol Rx, Llc USE OF pH SENSITIVE COMPOUNDS IN TASTE MASKING OF DRUG SUBSTANCES WITHIN ORAL THIN FILM STRIPS
US20110160264A1 (en) * 2009-12-28 2011-06-30 Monosol Rx, Llc Orally administrable film dosage forms containing ondansetron
WO2011081625A1 (en) 2009-12-30 2011-07-07 Novartis Ag Melt extruded thin strips containing coated pharmaceutical actives
WO2011081628A1 (en) 2009-12-30 2011-07-07 Novartis Ag Melt extruded nicotine thin strips
US20110178048A1 (en) * 2006-05-08 2011-07-21 Repka Michael A Stabilized formulation of triamcinolone acetonide
US20110200715A1 (en) * 2002-10-11 2011-08-18 Monosol Rx, Llc Multi-layer films having uniform content
US8007277B2 (en) 2006-08-25 2011-08-30 Ultradent Products, Inc. Non-custom dental treatment trays and mouth guards having improved anatomical features
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US8049426B2 (en) 2005-04-04 2011-11-01 Tessera, Inc. Electrostatic fluid accelerator for controlling a fluid flow
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US8114383B2 (en) 2003-08-06 2012-02-14 Gruenenthal Gmbh Abuse-proofed dosage form
US8114384B2 (en) 2004-07-01 2012-02-14 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US8192722B2 (en) 2003-08-06 2012-06-05 Grunenthal Gmbh Abuse-proof dosage form
US8202091B2 (en) 2007-08-31 2012-06-19 Ultradent Products, Inc. Dental treatment trays comprising silicone elastomeric material
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US8557286B1 (en) 1999-04-22 2013-10-15 Euroceltique, S.A. Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8652446B2 (en) 2000-03-17 2014-02-18 Lg Household & Healthcare Ltd. Apparatus and method for whitening teeth
US8663696B2 (en) 2007-10-19 2014-03-04 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
US8722086B2 (en) 2007-03-07 2014-05-13 Gruenenthal Gmbh Dosage form with impeded abuse
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8815289B2 (en) 2006-08-25 2014-08-26 Purdue Pharma L.P. Tamper resistant dosage forms
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8956160B2 (en) 2002-07-02 2015-02-17 Ranir, Llc Device and method for delivering an oral care agent
US8974826B2 (en) 2010-06-10 2015-03-10 Monosol Rx, Llc Nanoparticle film delivery systems
US9108340B2 (en) 2001-10-12 2015-08-18 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US9498410B2 (en) 2002-12-30 2016-11-22 Colgate-Palmolive Company Oral and personal care compositions and methods
US9554976B2 (en) 2002-09-11 2017-01-31 The Procter & Gamble Company Tooth whitening product
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US9642850B2 (en) 1997-02-24 2017-05-09 Purdue Pharma L.P. Method of providing sustained analgesia with buprenorphine
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
WO2017093941A1 (en) 2015-12-03 2017-06-08 Niconovum Usa, Inc. Multi-phase delivery compositions and products incorporating such compositions
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US9717682B2 (en) 2009-12-08 2017-08-01 Intelgenx Corporation Solid oral film dosage forms and methods for making same
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10034833B2 (en) 2009-08-07 2018-07-31 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US10058548B2 (en) 2003-08-06 2018-08-28 Grünenthal GmbH Abuse-proofed dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US10272607B2 (en) 2010-10-22 2019-04-30 Aquestive Therapeutics, Inc. Manufacturing of small film strips
US10285915B2 (en) 2012-10-17 2019-05-14 The Procter & Gamble Company Strip for the delivery of an oral care active and methods for applying oral care actives
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US10335373B2 (en) 2012-04-18 2019-07-02 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10449547B2 (en) 2013-11-26 2019-10-22 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP3663336A1 (en) * 2018-12-04 2020-06-10 Adhesives Research, Inc. Disintegrable thin film adhesive barrier
US10695297B2 (en) 2011-07-29 2020-06-30 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US10729658B2 (en) 2005-02-04 2020-08-04 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US11077068B2 (en) 2001-10-12 2021-08-03 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11191737B2 (en) 2016-05-05 2021-12-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US11224505B2 (en) 2018-11-02 2022-01-18 Rayner Intraocular Lenses Limited Hybrid accommodating intraocular lens assemblages including discrete lens unit with segmented lens haptics
US11224576B2 (en) 2003-12-24 2022-01-18 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US11452698B2 (en) 2013-03-15 2022-09-27 Smith & Nephew, Inc. Dissolvable gel-forming film for delivery of active agents
US11589980B2 (en) 2016-05-22 2023-02-28 Rayner Intraocular Lenses Limited Hybrid accommodating intraocular lens assemblages
US11672757B2 (en) 2017-06-28 2023-06-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Hot melt extrusion for pharmaceutical vaginal film products
US11844865B2 (en) 2004-07-01 2023-12-19 Grünenthal GmbH Abuse-proofed oral dosage form
US12016907B2 (en) 2012-11-14 2024-06-25 Smith & Nephew, Inc. Stable thermolysin hydrogel

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4292299A (en) * 1978-11-06 1981-09-29 Teijin Limited Slow-releasing medical preparation to be administered by adhering to a wet mucous surface
US4421738A (en) * 1979-07-31 1983-12-20 Eisai Co., Ltd. Sugar-coated tablet containing fat-soluble pharmaceutical material
US4517173A (en) * 1980-09-26 1985-05-14 Nippon Soda Co. Ltd. Mucous membrane-adhering film preparation and process for its preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4292299A (en) * 1978-11-06 1981-09-29 Teijin Limited Slow-releasing medical preparation to be administered by adhering to a wet mucous surface
US4421738A (en) * 1979-07-31 1983-12-20 Eisai Co., Ltd. Sugar-coated tablet containing fat-soluble pharmaceutical material
US4517173A (en) * 1980-09-26 1985-05-14 Nippon Soda Co. Ltd. Mucous membrane-adhering film preparation and process for its preparation

Cited By (323)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064650A (en) * 1988-04-19 1991-11-12 Southwest Research Institute Controlled-release salt sensitive capsule for oral use and adhesive system
US5135752A (en) * 1988-10-14 1992-08-04 Zetachron, Inc. Buccal dosage form
US5133971A (en) * 1988-12-14 1992-07-28 Phoebe Copelan Personal dental hygiene assembly
US5262164A (en) * 1989-11-17 1993-11-16 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US4997830A (en) * 1990-02-07 1991-03-05 The Research Foundation Of State University Of New York Pharmaceutical composition for the treatment of periodontitis
US5374457A (en) * 1990-08-28 1994-12-20 Viskase Corporation Transferable modifier-containing film
US5288532A (en) * 1990-08-28 1994-02-22 Viskase Corporation Transferable modifier-containing film
US5382391A (en) * 1990-08-28 1995-01-17 Viskase Corporation Method for producing transferable modifier-containing film
US5114718A (en) * 1990-09-20 1992-05-19 The Procter & Gamble Company Sustained release compositions for treating periodontol disease
US5112620A (en) * 1990-09-20 1992-05-12 Mikkur, Inc. Polyethylene glycol ointment for apthous ulcers
US5714165A (en) * 1990-09-20 1998-02-03 Mikkur, Inc. Bioadhesive polyethylene glycol ointment for medicaments
US5155144A (en) * 1990-10-29 1992-10-13 Manganaro James L Polysaccharide-based porous sheets
WO1992007640A1 (en) * 1990-10-29 1992-05-14 Fmc Corporation Polysaccharide-based porous sheets
US5998431A (en) 1991-08-23 1999-12-07 Gillette Canada Inc. Sustained-release matrices for dental application
US7338664B2 (en) 1991-08-23 2008-03-04 The Gillette Company Color changing matrix as wear indicator
US5851551A (en) * 1991-08-23 1998-12-22 The Gillette Company Sustained-release matrices for dental application
US5364634A (en) * 1991-11-08 1994-11-15 Southwest Research Institute Controlled-release PH sensitive capsule and adhesive system and method
US5906834A (en) * 1992-06-15 1999-05-25 The Gillette Company Color changing matrix as wear indicator
EP0598606A1 (en) * 1992-11-18 1994-05-25 JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. Extrudable compositions for topical or transdermal drug delivery
US5447725A (en) * 1993-06-11 1995-09-05 The Procter & Gamble Company Methods for aiding periodontal tissue regeneration
US5700478A (en) * 1993-08-19 1997-12-23 Cygnus, Inc. Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
US6068855A (en) 1994-11-03 2000-05-30 Euro-Celtique S. A. Pharmaceutical composition containing a fusible carrier and method for producing the same
US6743442B2 (en) 1994-11-04 2004-06-01 Euro-Celtique, S.A. Melt-extruded orally administrable opioid formulations
US20050089568A1 (en) * 1994-11-04 2005-04-28 Euro-Celtique S.A. Melt-extruded orally administrable opioid formulations
US5958452A (en) 1994-11-04 1999-09-28 Euro-Celtique, S.A. Extruded orally administrable opioid formulations
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US7510727B2 (en) 1994-11-04 2009-03-31 Purdue Pharma L.P. Melt-extrusion multiparticulates
US6706281B2 (en) 1994-11-04 2004-03-16 Euro-Celtique, S.A. Melt-extrusion multiparticulates
US6261599B1 (en) 1994-11-04 2001-07-17 Euro-Celtique, S.A. Melt-extruded orally administrable opioid formulations
US6335033B2 (en) 1994-11-04 2002-01-01 Euro-Celtique, S.A. Melt-extrusion multiparticulates
US5906814A (en) * 1995-12-07 1999-05-25 The Andrew Jergens Company Topical film-forming compositions
US5914118A (en) 1995-12-26 1999-06-22 Sanwa Kagaku Kenkyusho Co., Ltd. Multi-layered drug containing film preparation having powder adhesive thereon
US9642850B2 (en) 1997-02-24 2017-05-09 Purdue Pharma L.P. Method of providing sustained analgesia with buprenorphine
US7122199B2 (en) 1997-06-06 2006-10-17 The Procter & Gamble Company Methods for whitening teeth
US6884426B2 (en) 1997-06-06 2005-04-26 The Procter & Gamble Co. Methods for whitening teeth
US20030059381A1 (en) * 1997-06-06 2003-03-27 Goodhart Lesle Marie Structures and compositions increasing the stability of peroxide actives
US6551579B2 (en) 1997-06-06 2003-04-22 The Procter & Gamble Company Delivery systems for a tooth whitener
US5894017A (en) * 1997-06-06 1999-04-13 The Procter & Gamble Company Delivery system for an oral care substance using a strip of material having low flexural stiffness
US7018622B2 (en) 1997-06-06 2006-03-28 The Procter & Gamble Company Structures and compositions increasing the stability of peroxide actives
US6153210A (en) 1997-08-14 2000-11-28 Periodontix, Inc. Use of locally delivered metal ions for treatment of periodontal disease
US6562363B1 (en) 1997-09-26 2003-05-13 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US8557286B1 (en) 1999-04-22 2013-10-15 Euroceltique, S.A. Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix
US6231957B1 (en) 1999-05-06 2001-05-15 Horst G. Zerbe Rapidly disintegrating flavor wafer for flavor enrichment
US6375963B1 (en) 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
US6638881B2 (en) 1999-12-23 2003-10-28 Combe Incorporated Dental adhesive device and method of producing same
US6682721B2 (en) 2000-03-17 2004-01-27 Lg Household & Healthcare Ltd. Patches for teeth whitening
US8652446B2 (en) 2000-03-17 2014-02-18 Lg Household & Healthcare Ltd. Apparatus and method for whitening teeth
US7785572B2 (en) 2000-03-17 2010-08-31 Lg Household And Health Care Ltd. Method and device for teeth whitening using a dry type adhesive
US6689344B2 (en) 2000-03-17 2004-02-10 Lg Household & Healthcare Ltd. Patches for teeth whitening
US6780401B2 (en) 2000-03-17 2004-08-24 Lg Household & Healthcare Ltd. Patches for teeth whitening
US20040219111A1 (en) * 2000-03-17 2004-11-04 Ji-Young Kim Method and device for teeth whitening using a dry type adhesive
US20060193794A1 (en) * 2000-03-17 2006-08-31 Ji-Young Kim Patches for teeth whitening
US7862802B2 (en) 2000-03-17 2011-01-04 Lg Household & Health Care Ltd. Patches for teeth whitening
US8647607B2 (en) 2000-03-17 2014-02-11 Lg Household & Health Care Ltd. Patches for teeth whitening
US6566350B2 (en) * 2000-05-23 2003-05-20 Showa Yakuhin Kako Co., Ltd. Minocycline-containing compositions
US6582708B1 (en) 2000-06-28 2003-06-24 The Procter & Gamble Company Tooth whitening substance
US6514483B2 (en) * 2001-03-12 2003-02-04 Colgate Palmolive Company Strip for whitening tooth surfaces
US6503486B2 (en) * 2001-03-12 2003-01-07 Colgate Palmolive Company Strip for whitening tooth surfaces
US6419906B1 (en) * 2001-03-12 2002-07-16 Colgate Palmolive Company Strip for whitening tooth surfaces
US7132113B2 (en) 2001-06-19 2006-11-07 Intelgenx Corp. Flavored film
US20030053962A1 (en) * 2001-06-19 2003-03-20 Zerbe Horst G. Flavored film
US6660292B2 (en) 2001-06-19 2003-12-09 Hf Flavoring Technology Llp Rapidly disintegrating flavored film for precooked foods
US6946142B2 (en) 2001-06-23 2005-09-20 Lg Household & Healthcare Ltd. Multi-layer patches for teeth whitening
US20050196443A1 (en) * 2001-08-22 2005-09-08 Isis Pharmaceuticals, Inc. Pulsatile release compositions and methods for enhanced intestinal drug absorption
US7576067B2 (en) 2001-08-22 2009-08-18 Isis Pharmaceuticals, Inc. Pulsatile release compositions and methods for enhanced intestinal oligonucleotide drug absorption
US9855221B2 (en) 2001-10-12 2018-01-02 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11077068B2 (en) 2001-10-12 2021-08-03 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US10888499B2 (en) 2001-10-12 2021-01-12 Aquestive Therapeutics, Inc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8906277B2 (en) 2001-10-12 2014-12-09 Monosol Rx, Llc Process for manufacturing a resulting pharmaceutical film
US9108340B2 (en) 2001-10-12 2015-08-18 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20100221309A1 (en) * 2001-10-12 2010-09-02 Monosol Rx, Llc Film compositions for delivery of actives
US7824588B2 (en) 2001-10-12 2010-11-02 Monosol Rx, Llc Method of making self-supporting therapeutic active-containing film
US9931305B2 (en) 2001-10-12 2018-04-03 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7910641B2 (en) 2001-10-12 2011-03-22 Monosol Rx, Llc PH modulated films for delivery of actives
US20110182969A1 (en) * 2001-10-12 2011-07-28 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20080268027A1 (en) * 2001-10-12 2008-10-30 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20080260805A1 (en) * 2001-10-12 2008-10-23 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8685437B2 (en) 2001-10-12 2014-04-01 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20040258896A1 (en) * 2001-10-12 2004-12-23 Monosolrx Llc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US20080226695A1 (en) * 2001-10-12 2008-09-18 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8652378B1 (en) 2001-10-12 2014-02-18 Monosol Rx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20030167556A1 (en) * 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US20050037055A1 (en) * 2002-04-11 2005-02-17 Monosolrx Llc. Polyethylene oxide-based films and drug delivery systems made therefrom
US10111810B2 (en) 2002-04-11 2018-10-30 Aquestive Therapeutics, Inc. Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US6949240B2 (en) 2002-05-23 2005-09-27 The Procter & Gamble Company Tooth whitening products
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US10369109B2 (en) 2002-06-17 2019-08-06 Grünenthal GmbH Abuse-proofed dosage form
US8956160B2 (en) 2002-07-02 2015-02-17 Ranir, Llc Device and method for delivering an oral care agent
US20040120991A1 (en) * 2002-09-07 2004-06-24 Mars Incorporated Edible films having distinct regions
US20070269491A1 (en) * 2002-09-11 2007-11-22 The Procter & Gamble Company Tooth whitening strips
US10493016B2 (en) 2002-09-11 2019-12-03 The Procter & Gamble Company Tooth whitening product
US20070269388A1 (en) * 2002-09-11 2007-11-22 The Procter & Gamble Company Tooth whitening strips
US20070275023A1 (en) * 2002-09-11 2007-11-29 The Procter & Gamble Company Tooth whitening strips
US20050100515A1 (en) * 2002-09-11 2005-05-12 The Procter & Gamble Company Tooth whitening products
US20080038211A1 (en) * 2002-09-11 2008-02-14 Sagel Paul A Tooth whitening strips
US9554976B2 (en) 2002-09-11 2017-01-31 The Procter & Gamble Company Tooth whitening product
US20070269520A1 (en) * 2002-09-11 2007-11-22 The Procter & Gamble Company Tooth whitening strips
US20110200715A1 (en) * 2002-10-11 2011-08-18 Monosol Rx, Llc Multi-layer films having uniform content
US9498410B2 (en) 2002-12-30 2016-11-22 Colgate-Palmolive Company Oral and personal care compositions and methods
US9827172B2 (en) 2002-12-30 2017-11-28 Colgate-Palmolive Company Dentifrice containing functional film flakes
US9918909B2 (en) 2002-12-30 2018-03-20 Colgate-Palmolive Company Oral and personal care compositions and methods
US6964571B2 (en) 2003-01-24 2005-11-15 Ultradent Products, Inc. Pre-shaped dental trays and treatment devices and methods that utilize such dental trays
US7004756B2 (en) 2003-01-24 2006-02-28 Ultradent Products, Inc. Pre-shaped dental trays and treatment devices and methods that utilize such dental trays
US20050136381A1 (en) * 2003-01-24 2005-06-23 Andersen Scot N. Preshaped thin-walled dental trays and methods of manufacturing and using such trays
US20040146836A1 (en) * 2003-01-24 2004-07-29 Andersen Scot N. Pre-shaped dental trays and treatment devices and methods that utilize such dental trays
US7481653B2 (en) 2003-01-24 2009-01-27 Oratech Lc Preshaped thin-walled dental trays and methods of manufacturing and using such trays
US7040897B2 (en) 2003-05-23 2006-05-09 Ultradent Products, Inc. Thin, flexible membrane dental trays and systems and methods utilizing such trays
US6860736B2 (en) 2003-05-23 2005-03-01 Ultradent Products, Inc. Oral treatment devices that include a thin, flexible barrier layer and an endoskeleton treatment or adhesive composition
US7059857B2 (en) 2003-05-27 2006-06-13 Ultradent Products, Inc. Substantially solid desensitizing compositions and devices having a tray-like configuration and methods of manufacturing and using such compositions and devices
US7048543B2 (en) 2003-05-27 2006-05-23 Ultradent Products, Inc. Substantially solid bleaching composition in a tray-like configuration
US7074042B2 (en) 2003-05-27 2006-07-11 Ultradent Products, Inc. Tray-like dental bleaching devices having a barrier layer and a substantially solid bleaching composition
US20040241617A1 (en) * 2003-05-27 2004-12-02 Allred Peter M. Substantially solid desensitizing compositions and devices having a tray-like configuration and methods of manufacturing and using such compositions and devices
US7056118B2 (en) 2003-05-27 2006-06-06 Ultradent Products, Inc. Compositions and devices having a tray-like configuration for delivering a medicament and methods of manufacturing and using such compositions and devices
US20040241615A1 (en) * 2003-05-27 2004-12-02 Allred Peter M. Tray-like dental bleaching devices having a barrier layer and a substantially solid bleaching composition
US7052275B2 (en) 2003-05-27 2006-05-30 Ultradent Products, Inc. Kits and methods for bleaching and desensitizing teeth
US20040241616A1 (en) * 2003-05-27 2004-12-02 Ultradent Products, Inc. Substantially solid bleaching composition in a tray-like configuration
US20040241294A1 (en) * 2003-05-31 2004-12-02 Barabolak Roman M. Edible films including aspartame and methods of making same
US8420056B2 (en) 2003-08-06 2013-04-16 Grunenthal Gmbh Abuse-proofed dosage form
US8309060B2 (en) 2003-08-06 2012-11-13 Grunenthal Gmbh Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US10058548B2 (en) 2003-08-06 2018-08-28 Grünenthal GmbH Abuse-proofed dosage form
US8114383B2 (en) 2003-08-06 2012-02-14 Gruenenthal Gmbh Abuse-proofed dosage form
US8192722B2 (en) 2003-08-06 2012-06-05 Grunenthal Gmbh Abuse-proof dosage form
US9629807B2 (en) 2003-08-06 2017-04-25 Grünenthal GmbH Abuse-proofed dosage form
US10130591B2 (en) 2003-08-06 2018-11-20 Grünenthal GmbH Abuse-proofed dosage form
EP1659976A4 (en) * 2003-08-08 2009-03-04 Ultradent Products Inc Compositons and devices having a tray-like configuration for delivering an oral medicament and methods of manufacturing and using such compositions and devices
EP1659976A2 (en) * 2003-08-08 2006-05-31 Ultradent Products, Inc. Compositons and devices having a tray-like configuration for delivering an oral medicament and methods of manufacturing and using such compositions and devices
US6981874B2 (en) 2003-10-22 2006-01-03 Ultradent Products, Inc. Dental bleaching compositions and devices having a solid activation adhesive layer or region and bleaching gel layer or region
US20050089820A1 (en) * 2003-10-22 2005-04-28 Allred Peter M. Treatment compositions and strips having a solid adhesive layer and treatment gel adjacent thereto
US7011523B2 (en) 2003-10-22 2006-03-14 Ultradent Products, Inc. Bleaching compositions and devices having a solid adhesive layer and bleaching gel adjacent thereto
US6997708B2 (en) 2003-10-22 2006-02-14 Ultradent Products, Inc. Treatment compositions and strips having a solid adhesive layer and treatment gel adjacent thereto
US7470397B2 (en) 2003-10-24 2008-12-30 Adhesives Research, Inc. Disintegratable films for diagnostic devices
US9937123B2 (en) 2003-10-24 2018-04-10 Adhesives Research, Inc. Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents
US9585961B2 (en) 2003-10-24 2017-03-07 Adhesives Research, Inc. Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents
US7727466B2 (en) 2003-10-24 2010-06-01 Adhesives Research, Inc. Disintegratable films for diagnostic devices
US20080299005A1 (en) * 2003-10-24 2008-12-04 Meathrel William G Disintegratable films for diagnostic devices
US11224576B2 (en) 2003-12-24 2022-01-18 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US20080234200A1 (en) * 2003-12-26 2008-09-25 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US8277215B2 (en) 2004-02-19 2012-10-02 Ultradent Products, Inc. Universal non-custom dental tray having anatomical features to enhance fit
US20050186150A1 (en) * 2004-02-19 2005-08-25 Allred Peter M. Dental bleaching devices having a protective adhesive region
US20050186539A1 (en) * 2004-02-19 2005-08-25 Mclean Bruce S. Universal tray design having anatomical features to enhance fit
US9717577B2 (en) 2004-02-19 2017-08-01 Ultradent Products, Inc. Non-custom dental tray having anatomical cuspid-bicuspid cuts and/or V or U-shaped indentation in bottom wall
US7059858B2 (en) 2004-02-19 2006-06-13 Ultradent Products, Inc. Universal tray design having anatomical features to enhance fit
US7192280B2 (en) 2004-02-19 2007-03-20 Ultradent Products, Inc. Dental bleaching devices having a protective adhesive region
US20050208108A1 (en) * 2004-03-19 2005-09-22 Jannusch Leonard C Thermoplastic films and methods for making
US7264471B2 (en) 2004-05-05 2007-09-04 Ultradent Products, Inc. Methods and kits for bleaching teeth while protecting adjacent gingival tissue
US11844865B2 (en) 2004-07-01 2023-12-19 Grünenthal GmbH Abuse-proofed oral dosage form
US8323889B2 (en) 2004-07-01 2012-12-04 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US8114384B2 (en) 2004-07-01 2012-02-14 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US7625210B2 (en) 2004-08-09 2009-12-01 Ultradent Products, Inc. Treatment devices for providing oral treatments and kits and methods that utilize such treatment devices
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US8944819B2 (en) 2004-11-10 2015-02-03 Ranir, Llc Device and method for delivering an oral care agent
US20110086329A1 (en) * 2004-11-10 2011-04-14 Ranir/Dcp Corporation Device and method for delivering an oral care agent
US20080119698A1 (en) * 2004-11-30 2008-05-22 Tricca Robert E Systems and methods for intra-oral diagnosis
US7947508B2 (en) 2004-11-30 2011-05-24 Align Technology, Inc. Systems and methods for intra-oral diagnosis
US8075309B2 (en) 2004-11-30 2011-12-13 Align Technology, Inc. Systems and methods for intra-oral drug delivery
US20060115782A1 (en) * 2004-11-30 2006-06-01 Chunhua Li Systems and methods for coating a dental appliance
US20060115785A1 (en) * 2004-11-30 2006-06-01 Chunhua Li Systems and methods for intra-oral drug delivery
US20060116561A1 (en) * 2004-11-30 2006-06-01 Tricca Robert E Systems and methods for intra-oral diagnosis
US7766658B2 (en) 2004-11-30 2010-08-03 Align Technology, Inc. Systems and methods for intra-oral diagnosis
US8439674B2 (en) 2004-11-30 2013-05-14 Align Technology, Inc. Systems and methods for intra-oral drug delivery
US7247022B2 (en) 2005-01-31 2007-07-24 Ultradent Products, Inc. Dental tray system with releasable hold inner and outer dental trays
US20060172260A1 (en) * 2005-01-31 2006-08-03 Allred Peter M Dental tray system with releasable hold inner and outer dental trays
US20060171905A1 (en) * 2005-01-31 2006-08-03 Allred Peter M Dental bleaching compositions having a protective coating applied thereto
US10729658B2 (en) 2005-02-04 2020-08-04 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US10675278B2 (en) 2005-02-04 2020-06-09 Grünenthal GmbH Crush resistant delayed-release dosage forms
US20060207721A1 (en) * 2005-03-17 2006-09-21 Greg Slominski Polymer adhesive splicing of water-soluble, orally ingestible thin film webs
US8049426B2 (en) 2005-04-04 2011-11-01 Tessera, Inc. Electrostatic fluid accelerator for controlling a fluid flow
US7452209B2 (en) 2005-05-02 2008-11-18 Ultradent Products, Inc. Exoskeleton support for placement of a dental treatment strip
US20080200452A1 (en) * 2005-07-20 2008-08-21 Petra Obermeier Oral, Rapidly Disintegrating Film, Which Cannot be Spat Out, for a Neuroleptic
US20080318861A1 (en) * 2005-12-08 2008-12-25 Nastech Pharmaceutical Company Inc. Mucosal Delivery of Stabilized Formulations of Exendin
US20090130058A1 (en) * 2006-01-19 2009-05-21 Hall Mark J Biologically active composition comprising ethylcellulose
JP2009523793A (en) * 2006-01-19 2009-06-25 ダウ グローバル テクノロジーズ インコーポレイティド Bioactive composition comprising ethylcellulose
US9198865B2 (en) * 2006-01-19 2015-12-01 Dow Global Technologies Llc Biologically active composition comprising ethylcellulose
US20070172515A1 (en) * 2006-01-20 2007-07-26 Monosolrx, Llc Film bandage for mucosal administration of actives
US8465759B2 (en) 2006-03-24 2013-06-18 Auxilium Us Holdings, Llc Process for the preparation of a hot-melt extruded laminate
US20090264385A1 (en) * 2006-03-24 2009-10-22 Crowley Michael M Stabilized compositions containing alkaline labile drugs
US20090136555A1 (en) * 2006-03-24 2009-05-28 Crowley Michael M Process for the preparation of a hot-melt extruded laminate
WO2007112285A3 (en) * 2006-03-24 2008-10-02 Auxilium Pharmaceuticals Inc Process for the preparation of a hot-melt extruded laminate
CN101489756B (en) * 2006-03-24 2013-08-07 奥克思利尤姆国际控股公司 Process for the preparation of a hot-melt extruded laminate
EP3141248A1 (en) * 2006-03-24 2017-03-15 Auxilium International Holdings, Inc. Stabilized compositions containing alkaline labile drugs
AU2007230729B2 (en) * 2006-03-24 2011-07-28 Auxilium International Holdings, Inc. Process for the preparation of a hot-melt extruded laminate
WO2007112285A2 (en) 2006-03-24 2007-10-04 Auxilium Pharmaceuticals, Inc. Process for the preparation of a hot-melt extruded laminate
US9867786B2 (en) 2006-03-24 2018-01-16 Auxilium Us Holdings, Llc Stabilized compositions containing alkaline labile drugs
EP2010156A2 (en) * 2006-03-24 2009-01-07 Auxilium International Holdings, Inc. Stabilized compositions containing alkaline labile drugs
EP2010156A4 (en) * 2006-03-24 2012-07-18 Auxilium Int Holdings Inc Stabilized compositions containing alkaline labile drugs
US9364445B2 (en) 2006-03-24 2016-06-14 Auxilium Us Holdings, Llc Stabilized compositions containing alkaline labile drugs
US8173152B2 (en) 2006-03-24 2012-05-08 Auxilium Us Holdings, Llc Stabilized compositions containing alkaline labile drugs
US8883187B2 (en) 2006-03-24 2014-11-11 Auxilium Us Holdings, Llc Stabilized compositions containing alkaline labile drugs
US10335381B2 (en) 2006-05-08 2019-07-02 University Of Mississippi Stabilized formulation of triamcinolone acetonide
US9801837B2 (en) 2006-05-08 2017-10-31 The University Of Mississippi Stabilized formulation of triamcinolone acetonide
US20110178048A1 (en) * 2006-05-08 2011-07-21 Repka Michael A Stabilized formulation of triamcinolone acetonide
US20070298380A1 (en) * 2006-06-26 2007-12-27 Ultradent Products, Inc. Dental treatment devices adapted for improved lingual side adhesion
US20070298087A1 (en) * 2006-06-27 2007-12-27 Biegajski James E Two-phase mucoadhesive composition
US9084816B2 (en) 2006-08-25 2015-07-21 Purdue Pharma L.P. Tamper resistant dosage forms
US9763886B2 (en) 2006-08-25 2017-09-19 Purdue Pharma L.P. Tamper resistant dosage forms
US8894988B2 (en) 2006-08-25 2014-11-25 Purdue Pharma L.P. Tamper resistant dosage forms
US8894987B2 (en) 2006-08-25 2014-11-25 William H. McKenna Tamper resistant dosage forms
US11938225B2 (en) 2006-08-25 2024-03-26 Purdue Pharm L.P. Tamper resistant dosage forms
US10076499B2 (en) 2006-08-25 2018-09-18 Purdue Pharma L.P. Tamper resistant dosage forms
US9095615B2 (en) 2006-08-25 2015-08-04 Purdue Pharma L.P. Tamper resistant dosage forms
US9095614B2 (en) 2006-08-25 2015-08-04 Purdue Pharma L.P. Tamper resistant dosage forms
US9101661B2 (en) 2006-08-25 2015-08-11 Purdue Pharma L.P. Tamper resistant dosage forms
US8846086B2 (en) 2006-08-25 2014-09-30 Purdue Pharma L.P. Tamper resistant dosage forms
US10076498B2 (en) 2006-08-25 2018-09-18 Purdue Pharma L.P. Tamper resistant dosage forms
US11964056B1 (en) 2006-08-25 2024-04-23 Purdue Pharma L.P Tamper resistant dosage forms
US8834925B2 (en) 2006-08-25 2014-09-16 Purdue Pharma L.P. Tamper resistant dosage forms
US8821929B2 (en) 2006-08-25 2014-09-02 Purdue Pharma L.P. Tamper resistant dosage forms
US9486412B2 (en) 2006-08-25 2016-11-08 Purdue Pharma L.P. Tamper resistant dosage forms
US9486413B2 (en) 2006-08-25 2016-11-08 Purdue Pharma L.P. Tamper resistant dosage forms
US9492389B2 (en) 2006-08-25 2016-11-15 Purdue Pharma L.P. Tamper resistant dosage forms
US9492391B2 (en) 2006-08-25 2016-11-15 Purdue Pharma L.P. Tamper resistant dosage forms
US9492393B2 (en) 2006-08-25 2016-11-15 Purdue Pharma L.P. Tamper resistant dosage forms
US9492390B2 (en) 2006-08-25 2016-11-15 Purdue Pharma L.P. Tamper resistant dosage forms
US9492392B2 (en) 2006-08-25 2016-11-15 Purdue Pharma L.P. Tamper resistant dosage forms
US8815289B2 (en) 2006-08-25 2014-08-26 Purdue Pharma L.P. Tamper resistant dosage forms
US9545380B2 (en) 2006-08-25 2017-01-17 Purdue Pharma L.P. Tamper resistant dosage forms
US8721332B2 (en) 2006-08-25 2014-05-13 Ultradent Products, Inc. Non-custom dental treatment trays having improved anatomical features
US11904055B2 (en) 2006-08-25 2024-02-20 Purdue Pharma L.P. Tamper resistant dosage forms
US8007277B2 (en) 2006-08-25 2011-08-30 Ultradent Products, Inc. Non-custom dental treatment trays and mouth guards having improved anatomical features
US11298322B2 (en) 2006-08-25 2022-04-12 Purdue Pharma L.P. Tamper resistant dosage forms
US9775810B2 (en) 2006-08-25 2017-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US9775812B2 (en) 2006-08-25 2017-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US9775811B2 (en) 2006-08-25 2017-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US11826472B2 (en) 2006-08-25 2023-11-28 Purdue Pharma L.P. Tamper resistant dosage forms
US11304909B2 (en) 2006-08-25 2022-04-19 Purdue Pharma L.P. Tamper resistant dosage forms
US9775809B2 (en) 2006-08-25 2017-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US9775808B2 (en) 2006-08-25 2017-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US8444413B2 (en) 2006-08-25 2013-05-21 Ultradent Products, Inc. Non-custom dental treatment trays having improved anatomical features
US9770417B2 (en) 2006-08-25 2017-09-26 Purdue Pharma L.P. Tamper resistant dosage forms
US11304908B2 (en) 2006-08-25 2022-04-19 Purdue Pharma L.P. Tamper resistant dosage forms
US9770416B2 (en) 2006-08-25 2017-09-26 Purdue Pharma L.P. Tamper resistant dosage forms
US9763933B2 (en) 2006-08-25 2017-09-19 Purdue Pharma L.P. Tamper resistant dosage forms
US8911719B2 (en) 2006-08-25 2014-12-16 Purdue Pharma Lp Tamper resistant dosage forms
US7972618B2 (en) 2006-09-20 2011-07-05 Monosol Rx, Llc Edible water-soluble film containing a foam reducing flavoring agent
US20080075825A1 (en) * 2006-09-20 2008-03-27 Fuisz Richard C Edible Water-Soluble Film Containing a Foam Reducing Flavoring Agent
US8722086B2 (en) 2007-03-07 2014-05-13 Gruenenthal Gmbh Dosage form with impeded abuse
US20080292683A1 (en) * 2007-05-24 2008-11-27 Monosolrx, Llc. Film shreds and delivery system incorporating same
US8202091B2 (en) 2007-08-31 2012-06-19 Ultradent Products, Inc. Dental treatment trays comprising silicone elastomeric material
US9949809B2 (en) 2007-08-31 2018-04-24 Ultradent Products, Inc. Dental treatment devices comprising silicone-like elastomeric material
US11033374B2 (en) 2007-08-31 2021-06-15 Ultradent Products, Inc. Dental treatment devices comprising silicone-like elastomeric material
US20090087812A1 (en) * 2007-10-02 2009-04-02 Ultradent Products, Inc. Self-customizable dental treatment trays
US8613285B2 (en) 2007-10-11 2013-12-24 Philip Morris Products S.A. Extrudable and extruded compositions for delivery of bioactive agents, method of making same and method of using same
WO2009048606A1 (en) 2007-10-11 2009-04-16 Fuisz Richard C Extrudable and extruded compositions for delivery of bioactive agents, method of making the same and method of using same
US20090095313A1 (en) * 2007-10-11 2009-04-16 Fuisz Richard C Smokeless Tobacco Product, Smokeless Tobacco Product in the Form of a Sheet, Extrudable Tobacco Composition, Method for Manufacturing a Smokeless Tobacco Product, Method for Delivering Super Bioavailable Nicotine Contained in Tobacco to a User, and Packaged Smokeless Tobacco Product Sheet
US20090098192A1 (en) * 2007-10-11 2009-04-16 Fuisz Richard C Extrudable and Extruded Compositions for Delivery of Bioactive Agents, Method of Making Same and Method of Using Same
US9125434B2 (en) 2007-10-11 2015-09-08 Philip Morris Products S.A. Smokeless tobacco product, smokeless tobacco product in the form of a sheet, extrudable tobacco composition, method for manufacturing a smokeless tobacco product, method for delivering super bioavailable nicotine contained in tobacco to a user, and packaged smokeless tobacco product sheet
WO2009048522A1 (en) 2007-10-11 2009-04-16 Richard Fuisz Smokeless tobacco product
US10334872B2 (en) 2007-10-11 2019-07-02 Philip Morris Products S.A. Smokeless tobacco product, smokeless tobacco product in the form of a sheet, extrudable tobacco composition, method for manufacturing a smokeless tobacco product, method for delivering super bioavailable nicotine contained in tobacco to a user, and packaged smokeless tobacco product sheet
US8663696B2 (en) 2007-10-19 2014-03-04 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
US9750701B2 (en) 2008-01-25 2017-09-05 Grünenthal GmbH Pharmaceutical dosage form
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
US20110009834A1 (en) * 2008-03-15 2011-01-13 Lts Lohmann Therapie-Systeme Ag Gingival wafer
US8647314B2 (en) * 2008-03-15 2014-02-11 Lts Lohmann Therapie-Systeme Ag Gingival wafer
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US20100028829A1 (en) * 2008-07-31 2010-02-04 Ultradent Products, Inc. Chemically activated dental bleaching trays
US20100040727A1 (en) * 2008-08-18 2010-02-18 Monosol Rx, Llc Method for Improving Uniformity of Content in Edible Film Manufacturing
US8282954B2 (en) 2008-12-15 2012-10-09 Monosol Rx, Llc Method for manufacturing edible film
US20100150987A1 (en) * 2008-12-15 2010-06-17 Monosol Rx, Llc Method for Manufacturing Edible Film
US20100285130A1 (en) * 2009-05-06 2010-11-11 Monosol Rx, Llc Coating of complexed actives in film formulations
US20100297232A1 (en) * 2009-05-19 2010-11-25 Monosol Rx, Llc Ondansetron film compositions
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10493033B2 (en) 2009-07-22 2019-12-03 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10034833B2 (en) 2009-08-07 2018-07-31 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US10821074B2 (en) 2009-08-07 2020-11-03 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US11135216B2 (en) 2009-08-07 2021-10-05 Indivior Uk Limited Sublingual and buccal film compositions
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US9687454B2 (en) 2009-08-07 2017-06-27 Indivior Uk Limited Sublingual and buccal film compositions
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US9717682B2 (en) 2009-12-08 2017-08-01 Intelgenx Corporation Solid oral film dosage forms and methods for making same
US20110142942A1 (en) * 2009-12-10 2011-06-16 Monosol Rx, Llc USE OF pH SENSITIVE COMPOUNDS IN TASTE MASKING OF DRUG SUBSTANCES WITHIN ORAL THIN FILM STRIPS
US20110160264A1 (en) * 2009-12-28 2011-06-30 Monosol Rx, Llc Orally administrable film dosage forms containing ondansetron
WO2011081625A1 (en) 2009-12-30 2011-07-07 Novartis Ag Melt extruded thin strips containing coated pharmaceutical actives
WO2011081628A1 (en) 2009-12-30 2011-07-07 Novartis Ag Melt extruded nicotine thin strips
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US8974826B2 (en) 2010-06-10 2015-03-10 Monosol Rx, Llc Nanoparticle film delivery systems
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US10940626B2 (en) 2010-10-22 2021-03-09 Aquestive Therapeutics, Inc. Manufacturing of small film strips
US10272607B2 (en) 2010-10-22 2019-04-30 Aquestive Therapeutics, Inc. Manufacturing of small film strips
US10864164B2 (en) 2011-07-29 2020-12-15 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US10695297B2 (en) 2011-07-29 2020-06-30 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US10335373B2 (en) 2012-04-18 2019-07-02 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10285916B2 (en) 2012-10-17 2019-05-14 The Procter & Gamble Company Strip for the delivery of an oral care active and methods for applying oral care actives
US10285915B2 (en) 2012-10-17 2019-05-14 The Procter & Gamble Company Strip for the delivery of an oral care active and methods for applying oral care actives
US12016907B2 (en) 2012-11-14 2024-06-25 Smith & Nephew, Inc. Stable thermolysin hydrogel
US12023412B2 (en) 2013-03-15 2024-07-02 Smith & Nephew, Inc. Dissolvable gel-forming film for delivery of active agents
US11452698B2 (en) 2013-03-15 2022-09-27 Smith & Nephew, Inc. Dissolvable gel-forming film for delivery of active agents
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US10449547B2 (en) 2013-11-26 2019-10-22 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
WO2017093941A1 (en) 2015-12-03 2017-06-08 Niconovum Usa, Inc. Multi-phase delivery compositions and products incorporating such compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US11191737B2 (en) 2016-05-05 2021-12-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12023309B2 (en) 2016-05-05 2024-07-02 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11589980B2 (en) 2016-05-22 2023-02-28 Rayner Intraocular Lenses Limited Hybrid accommodating intraocular lens assemblages
US11672757B2 (en) 2017-06-28 2023-06-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Hot melt extrusion for pharmaceutical vaginal film products
US11224505B2 (en) 2018-11-02 2022-01-18 Rayner Intraocular Lenses Limited Hybrid accommodating intraocular lens assemblages including discrete lens unit with segmented lens haptics
EP3663336A1 (en) * 2018-12-04 2020-06-10 Adhesives Research, Inc. Disintegrable thin film adhesive barrier

Similar Documents

Publication Publication Date Title
USRE33093E (en) Bioadhesive extruded film for intra-oral drug delivery and process
US4713243A (en) Bioadhesive extruded film for intra-oral drug delivery and process
AU679937B2 (en) Extrudable compositions for topical or transdermal drug delivery
US4307075A (en) Topical treatment of aphthous stomatitis
JP3964465B2 (en) Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US6072100A (en) Extrudable compositions for topical or transdermal drug delivery
US5780045A (en) Transmucosal drug delivery device
US6375963B1 (en) Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
US9161909B2 (en) Adhesive compositions for the treatment of xerostomia
JP4619894B2 (en) Drug carrier device suitable for delivery of drug compounds to mucosal surfaces
US6585997B2 (en) Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
EP0200508B1 (en) Adhesive oral bandages and oral pharmaceutical preparations
JPH09504810A (en) Water-soluble pressure sensitive mucoadhesive
US20090053309A1 (en) Adhesive compositions for the treatment of xerostomia
GB2574878A (en) Oral compositions and mucoadhesive thin films formed therefrom
US20020192287A1 (en) Extrudable compositions for topical or transdermal drug delivery
EP2889030A1 (en) Controlling the erosion rates of mucoadhesive devices that deliver actives and other compounds and providing increased and variable therapeutic blood levels
JP6806388B1 (en) An anti-inflammatory liquid composition for covering the oral mucosa, and a pharmaceutical composition for preventing and / or treating aphthous ulcer using the same.
CA2366411A1 (en) Topical medicated bioadhesive compositions and methods of use and preparation thereof
JPS62255417A (en) Pharmaceutical preparation for oral cavity
AU769500B2 (en) Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12